Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vitro Biopharma's Revenue for the
three
months ended in Oct. 2022 was $3.29 Mil. Vitro Biopharma's average Accounts Receivable for the
three
months ended in Oct. 2022 was $0.10 Mil.
Hence, Vitro Biopharma's Receivables Turnover for the
three
months ended in Oct. 2022 was 32.77.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vitro Biopharma Receivables Turnover Related Terms
Vitro Biopharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Vitro Biopharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vitro Biopharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitro Biopharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vitro Biopharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vitro Biopharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitro Biopharma (VTRO) has a Receivables Turnover of 32.77 as of Oct. 2022. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vitro Biopharma and its competitors.
Is Vitro Biopharma's Receivables Turnover too high?
Vitro Biopharma's current Receivables Turnover is 32.77. The Biotechnology industry median Receivables Turnover is 5.28. Vitro Biopharma's value of 32.77 is 520.6% above this industry median.
How does Vitro Biopharma's Receivables Turnover compare to ?
Vitro Biopharma's Receivables Turnover of 32.77 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.28. Vitro Biopharma's value of 32.77 is 520.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitro Biopharma's current Receivables Turnover of 32.77 is 520.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vitro Biopharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitro Biopharma's current Receivables Turnover is 32.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Receivables Turnover of 32.77. The current Receivables Turnover is 32.77 and 520.6% above the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Receivables Turnover is 32.77 as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTRO has been successfully added to your 
